{"id":12447,"date":"2026-11-04T13:29:01","date_gmt":"2026-11-04T12:29:01","guid":{"rendered":"https:\/\/mumak.me\/?p=12447"},"modified":"2026-11-04T14:00:56","modified_gmt":"2026-11-04T13:00:56","slug":"palantir-q3-2026-earnings-update-2","status":"publish","type":"post","link":"https:\/\/mumak.me\/en\/portfolio-updates\/company-update\/palantir-q3-2026-earnings-update-2\/","title":{"rendered":"Bayer \u2013 Q3 2026 Earnings Update"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"12447\" class=\"elementor elementor-12447 elementor-12446\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e1ac738 e-flex e-con-boxed e-con e-parent\" data-id=\"e1ac738\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b8e9f5a elementor-widget elementor-widget-text-editor\" data-id=\"b8e9f5a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\"><strong>Bayer<\/strong> recorded rising revenue and an improved adjusted operating result in the third quarter of 2026. The main growth driver was the pharmaceutical business, particularly the positive development of the drugs Nubeqa and Kerendia. On this basis, the Group raised its earnings and cash flow guidance for the full year.<\/p><p>At the same time, the weaker development in the agricultural business, negative free cash flow, and persistent legal risks weigh on the overall financial picture.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e410360 elementor-widget elementor-widget-gn_tradingview_chart\" data-id=\"e410360\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"gn_tradingview_chart.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t        <div class=\"gn-tv-widget gn-tv-widget--chart\" style=\"--gn-tv-height: 450px; --gn-tv-min-height: 450px;\" data-gn-tv-type=\"symbol-overview\" data-gn-tv-config=\"{&quot;lineWidth&quot;:2,&quot;lineType&quot;:0,&quot;chartType&quot;:&quot;area&quot;,&quot;showVolume&quot;:true,&quot;fontColor&quot;:&quot;rgb(106, 109, 120)&quot;,&quot;gridLineColor&quot;:&quot;rgba(46, 46, 46, 0.06)&quot;,&quot;volumeUpColor&quot;:&quot;rgba(34, 171, 148, 0.5)&quot;,&quot;volumeDownColor&quot;:&quot;rgba(247, 82, 95, 0.5)&quot;,&quot;backgroundColor&quot;:&quot;#ffffff&quot;,&quot;widgetFontColor&quot;:&quot;rgba(69, 56, 42, 1)&quot;,&quot;upColor&quot;:&quot;#22ab94&quot;,&quot;downColor&quot;:&quot;#f7525f&quot;,&quot;borderUpColor&quot;:&quot;#22ab94&quot;,&quot;borderDownColor&quot;:&quot;#f7525f&quot;,&quot;wickUpColor&quot;:&quot;#22ab94&quot;,&quot;wickDownColor&quot;:&quot;#f7525f&quot;,&quot;colorTheme&quot;:&quot;light&quot;,&quot;isTransparent&quot;:false,&quot;locale&quot;:&quot;en&quot;,&quot;chartOnly&quot;:false,&quot;scalePosition&quot;:&quot;right&quot;,&quot;scaleMode&quot;:&quot;Normal&quot;,&quot;fontFamily&quot;:&quot;Inter, -apple-system, BlinkMacSystemFont, Trebuchet MS, Roboto, Ubuntu, sans-serif&quot;,&quot;valuesTracking&quot;:&quot;1&quot;,&quot;changeMode&quot;:&quot;price-and-percent&quot;,&quot;symbols&quot;:[[&quot;XETR:BAYN|12M&quot;]],&quot;dateRanges&quot;:[&quot;1d|1&quot;,&quot;1m|30&quot;,&quot;3m|60&quot;,&quot;12m|1D&quot;,&quot;60m|1W&quot;,&quot;all|1M&quot;],&quot;fontSize&quot;:&quot;10&quot;,&quot;headerFontSize&quot;:&quot;medium&quot;,&quot;autosize&quot;:true,&quot;width&quot;:&quot;100%&quot;,&quot;height&quot;:&quot;100%&quot;,&quot;noTimeScale&quot;:false,&quot;hideDateRanges&quot;:false,&quot;showMA&quot;:false,&quot;maLength&quot;:9,&quot;maLineColor&quot;:&quot;#2962FF&quot;,&quot;maLineWidth&quot;:1,&quot;hideMarketStatus&quot;:false,&quot;hideSymbolLogo&quot;:false}\">\n            <div class=\"gn-tv-widget__inner\">\n                <div class=\"gn-tv-widget__embed gn-tv-widget__chart\">\n                    <div class=\"tradingview-widget-container__widget\"><\/div>\n                <\/div>\n            <\/div>\n        <\/div>\n        \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-9a58f06 e-flex e-con-boxed e-con e-parent\" data-id=\"9a58f06\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f904adb elementor-widget elementor-widget-html\" data-id=\"f904adb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t\n<style>\/* MUMAK Finanzkennzahlen *\/\n.mumak-financial {\n  --navy: #29485A;\n  --gold: #C89B50;\n  --cream: #FAF7F2;\n  --line: #E5E7E8;\n  font-family: inherit;\n  color: var(--navy);\n  max-width: 100%;\n  margin: 28px 0;\n}\n\n.mumak-financial * {\n  box-sizing: border-box;\n}\n\n.mumak-financial .mf-header {\n  border-left: 4px solid var(--gold);\n  padding-left: 17px;\n  margin-bottom: 22px;\n}\n\n.mumak-financial .mf-eyebrow {\n  color: var(--gold);\n  font-size: 11px;\n  font-weight: 700;\n  letter-spacing: 1.5px;\n  text-transform: uppercase;\n  margin-bottom: 7px;\n}\n\n.mumak-financial .mf-title {\n  font-size: clamp(21px, 3vw, 28px);\n  line-height: 1.25;\n  font-weight: 700;\n  color: var(--navy);\n  margin: 0 0 7px;\n}\n\n.mumak-financial .mf-subtitle {\n  font-size: 13px;\n  color: #697780;\n  margin: 0;\n}\n\n.mumak-financial .mf-kpis {\n  display: grid;\n  grid-template-columns: repeat(4, minmax(0, 1fr));\n  gap: 12px;\n  margin-bottom: 25px;\n}\n\n.mumak-financial .mf-kpi {\n  background: var(--cream);\n  border: 1px solid #EAE4DB;\n  border-radius: 9px;\n  padding: 18px 13px;\n  min-width: 0;\n}\n\n.mumak-financial .mf-value {\n  display: block;\n  font-size: clamp(19px, 2.3vw, 27px);\n  font-weight: 700;\n  color: var(--navy);\n  line-height: 1.2;\n  margin-bottom: 9px;\n  font-variant-numeric: tabular-nums;\n}\n\n.mumak-financial .mf-label {\n  display: block;\n  font-size: 12px;\n  font-weight: 600;\n  line-height: 1.4;\n}\n\n.mumak-financial .mf-detail {\n  display: block;\n  margin-top: 7px;\n  font-size: 11px;\n  color: #7A858A;\n}\n\n.mumak-financial .mf-section-title {\n  font-size: 18px;\n  font-weight: 700;\n  color: var(--navy);\n  margin: 0 0 13px;\n}\n\n.mumak-financial .mf-table-wrap {\n  width: 100%;\n  overflow-x: auto;\n  border: 1px solid var(--line);\n  border-radius: 9px;\n  margin-bottom: 24px;\n}\n\n.mumak-financial table {\n  width: 100%;\n  min-width: 470px;\n  border-collapse: collapse;\n  border: 0;\n  margin: 0;\n  font-size: 13px;\n  background: #FFFFFF;\n}\n\n.mumak-financial table thead th {\n  background: var(--navy);\n  color: #FFFFFF;\n  font-size: 11px;\n  letter-spacing: .5px;\n  text-transform: uppercase;\n  padding: 14px 15px;\n  border: 0;\n}\n\n.mumak-financial table th:first-child,\n.mumak-financial table td:first-child {\n  text-align: left;\n  width: 52%;\n}\n\n.mumak-financial table th:not(:first-child),\n.mumak-financial table td:not(:first-child) {\n  text-align: right;\n}\n\n.mumak-financial table tbody td {\n  padding: 13px 15px;\n  border: 0;\n  border-bottom: 1px solid var(--line);\n  vertical-align: middle;\n  font-variant-numeric: tabular-nums;\n}\n\n.mumak-financial table tbody tr:nth-child(even) {\n  background: #FAFAF9;\n}\n\n.mumak-financial table tbody tr:last-child td {\n  border-bottom: 0;\n}\n\n.mumak-financial .mf-amount {\n  font-weight: 600;\n}\n\n.mumak-financial .mf-outlook {\n  background: var(--cream);\n  border: 1px solid #EAE4DB;\n  border-left: 4px solid var(--gold);\n  border-radius: 8px;\n  padding: 22px;\n  margin-top: 8px;\n}\n\n.mumak-financial .mf-outlook-title {\n  font-size: 18px;\n  font-weight: 700;\n  margin: 0 0 18px;\n}\n\n.mumak-financial .mf-forecast {\n  display: grid;\n  grid-template-columns: repeat(2, minmax(0, 1fr));\n  gap: 18px;\n}\n\n.mumak-financial .mf-forecast-label {\n  display: block;\n  font-size: 12px;\n  color: #66747D;\n  margin-bottom: 7px;\n}\n\n.mumak-financial .mf-forecast-value {\n  display: block;\n  font-size: clamp(17px, 2.4vw, 23px);\n  font-weight: 700;\n  line-height: 1.3;\n  overflow-wrap: anywhere;\n}\n\n.mumak-financial .mf-source {\n  margin-top: 15px;\n  font-size: 11px;\n  line-height: 1.6;\n  color: #758087;\n}\n\n\/* Mobile Darstellung *\/\n@media (max-width: 767px) {\n  .mumak-financial .mf-kpis {\n    grid-template-columns: repeat(2, minmax(0, 1fr));\n    gap: 9px;\n  }\n\n  .mumak-financial .mf-kpi {\n    padding: 15px 11px;\n  }\n\n  .mumak-financial .mf-forecast {\n    grid-template-columns: 1fr;\n    gap: 17px;\n  }\n\n  .mumak-financial .mf-outlook {\n    padding: 18px 15px;\n  }\n\n  .mumak-financial table {\n    font-size: 12px;\n  }\n  \n\n\/* BAYER \u2013 3 KPI CARDS PER ROW *\/\n.mumak-financial .mf-kpis {\n  display: grid !important;\n  grid-template-columns: repeat(3, 1fr) !important;\n  gap: 12px !important;\n}\n\n.mumak-financial .mf-kpis > .mf-kpi {\n  width: auto !important;\n  min-width: 0 !important;\n  max-width: none !important;\n  grid-column: auto !important;\n}\n\n\/* MOBILE \u2013 2 PER ROW *\/\n@media (max-width: 767px) {\n  .mumak-financial .mf-kpis {\n    grid-template-columns: repeat(2, 1fr) !important;\n  }\n}\n\n\n}\n<\/style><section class=\"mumak-financial\" lang=\"de\" aria-label=\"Palantir Finanzkennzahlen Q3 2026\"><!-- \u00dcBERSCHRIFT --><div class=\"mf-header\"><div class=\"mf-eyebrow\">MUMAK \u00b7 UNTERNEHMENSUPDATE<\/div><h2 class=\"mf-title\">Bayer | Q3 2026<\/h2><p class=\"mf-subtitle\">Finanzergebnisse \u00b7 Vorjahresvergleich\n  <\/p><\/div><!-- WICHTIGSTE KENNZAHLEN --><div class=\"mf-kpis\"><div class=\"mf-kpi\"><span class=\"mf-value\">10,05 Mrd. \u20ac<\/span><span class=\"mf-label\">Konzernumsatz<\/span><span class=\"mf-detail\" style=\"color:#27845B;font-weight:600;\">+4,1 % zum Vorjahr\n    <\/span><\/div><div class=\"mf-kpi\"><span class=\"mf-value\">1,62 Mrd. \u20ac<\/span><span class=\"mf-label\">EBITDA vor Sondereinfl\u00fcssen<\/span><span class=\"mf-detail\" style=\"color:#27845B;font-weight:600;\">+6,9 % zum Vorjahr\n    <\/span><\/div><div class=\"mf-kpi\"><span class=\"mf-value\">0,31 \u20ac<\/span><span class=\"mf-label\">Bereinigtes Ergebnis je Aktie<\/span><span class=\"mf-detail\" style=\"color:#B45353;font-weight:600;\">\u221236,7 % zum Vorjahr\n    <\/span><\/div><div class=\"mf-kpi\"><span class=\"mf-value\">\u2212672 Mio. \u20ac<\/span><span class=\"mf-label\">Konzernergebnis<\/span><span class=\"mf-detail\" style=\"color:#27845B;font-weight:600;\">Verlust verringert\n    <\/span><\/div><div class=\"mf-kpi\"><span class=\"mf-value\">\u2212293 Mio. \u20ac<\/span><span class=\"mf-label\">Free Cashflow<\/span><span class=\"mf-detail\">Q3 2025: +596 Mio. \u20ac\n    <\/span><\/div><div class=\"mf-kpi\"><span class=\"mf-value\">31,08 Mrd. \u20ac<\/span><span class=\"mf-label\">Nettofinanzverschuldung<\/span><span class=\"mf-detail\" style=\"color:#27845B;font-weight:600;\">\u22125,0 % zum Vorjahr\n    <\/span><\/div><\/div><!-- QUELLE --><p style=\"font-size:12px;color:#6B7280;margin-top:16px;\">Quelle: Bayer, Quartalsmitteilung Q3 2026.\n  \n  \n<\/p><!-- FINANZTABELLE --><h3 class=\"mf-section-title\">Finanzkennzahlen im Detail\n  <\/h3><div class=\"mf-table-wrap\" role=\"region\" aria-label=\"Tabelle der Finanzkennzahlen\" tabindex=\"0\"><table><thead><tr><th scope=\"col\">Kennzahl<\/th><th scope=\"col\">Q3 2026<\/th><th scope=\"col\">Ver\u00e4nderung zum Vorjahr<\/th><\/tr><\/thead><tbody><tr><td>Konzernumsatz<\/td><td class=\"mf-amount\">10,05 Mrd. EUR<\/td><td style=\"padding:11px;text-align:right;color:#27845B;font-weight:700;\">+4,1 %<\/td><\/tr><\/tr><tr><td>EBITDA vor Sondereinfl\u00fcssen<\/td><td class=\"mf-amount\">1,62 Mrd. EUR<\/td><td style=\"padding:11px;text-align:right;color:#27845B;font-weight:700;\">+6,9 %<\/td><\/tr><tr><td>EBITDA-Marge vor Sondereinfl\u00fcssen<\/td><td class=\"mf-amount\">16,1 %<\/td><td style=\"padding:11px;text-align:right;color:#27845B;font-weight:700;\">+0,5 PP<\/td><\/tr><tr><td>Bereinigtes Ergebnis je Aktie<\/td><td class=\"mf-amount\">0,31 EUR<\/td><td style=\"padding:11px;text-align:right;color:#B45353;font-weight:700;\">\u221236,7 %<\/td><\/tr><tr><td>Konzernergebnis\n          <\/td><td class=\"mf-amount\">\u2212672 Mio. EUR<\/td><td style=\"padding:11px;text-align:right;color:#27845B;font-weight:700;\">Verlust reduziert<\/td><\/tr><tr><td>Free Cashflow\n          <\/td><td class=\"mf-amount\">\u2212293 Mio. EUR<\/td><td> Vorjahr: +596 Mio. EUR<\/td><\/tr><tr><td>Nettofinanzverschuldung<\/td><td class=\"mf-amount\">31,08 Mrd. EUR<\/td><td style=\"padding:11px;text-align:right;color:#27845B;font-weight:700;\">\u22125,0 %<\/td><\/tr><\/tr><\/tbody><\/table><\/div><\/div><\/div><!-- QUELLENANGABE --><p class=\"mf-source\">Quelle: Bayer,\n    Quartalsmitteilung Q3 2026.\n  <\/p><\/section>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5888df6 elementor-widget elementor-widget-text-editor\" data-id=\"5888df6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\">Currency and portfolio-adjusted Group revenue rose by 1.9%. The improvement in EBITDA before special items was primarily driven by the Pharmaceuticals division.<\/p><p>The Group net income remained negative, partly due to impairments and expenses related to litigation.<\/p><h2>Pharmaceuticals: Key Growth Driver<\/h2><p>The Pharmaceuticals division achieved revenue of EUR 4.68 billion. On a currency and portfolio-adjusted basis, this represents growth of 6.4%.<\/p><p>Two key drugs developed particularly positively:<\/p><ul data-spread=\"false\"><li><p><strong>Nubeqa<\/strong>, for the treatment of prostate cancer, recorded currency and portfolio-adjusted revenue growth of 58.3% and reached quarterly revenue of approximately EUR 1 billion.<\/p><\/li><li><p><strong>Kerendia<\/strong>, for the treatment of chronic kidney disease and heart failure, achieved revenue growth of 64.9% on the same basis.<\/p><\/li><\/ul><p>EBITDA before special items for the Pharmaceuticals division increased by 23.6% to EUR 1.29 billion. The corresponding margin reached 27.6%.<\/p><p>The development shows that newer drugs are increasingly compensating for the declining revenue of established products such as Xarelto and Eylea. The latter remain under pressure due to patent expirations.<\/p><h2>Crop Science and Consumer Health: Mixed Development<\/h2><p><strong>Crop Science<\/strong> achieved revenue of EUR 3.88 billion. On a currency and portfolio-adjusted basis, this represents a decline of 2.4%.<\/p><p>EBITDA before special items fell by 41.3% to EUR 101 million. Higher costs and weaker demand in parts of the crop protection business had a negative impact.<\/p><p><strong>Consumer Health<\/strong> generated revenue of EUR 1.45 billion. Currency and portfolio-adjusted revenue remained almost unchanged compared to the prior-year quarter.<\/p><p>EBITDA before special items decreased by 4.4% to EUR 347 million. Higher marketing investments and a challenging market environment weighed on profitability.<\/p><p>The results highlight the varying operational performance of the three business segments.<\/p><h2>Bayer Raises Full-Year Guidance for 2026<\/h2><p>Due to the improved development in the pharmaceutical business, Bayer adjusted several financial targets for the full year upwards.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e3962c elementor-widget elementor-widget-html\" data-id=\"4e3962c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t\n<style>\/* MUMAK Bayer Prognose 2026 *\/\n.mumak-guidance {\n  --navy: #29485A;\n  --gold: #C89B50;\n  --cream: #FAF7F2;\n  --green: #27845B;\n  font-family: inherit;\n  color: var(--navy);\n  margin: 28px 0;\n  width: 100%;\n}\n\n.mumak-guidance * {\n  box-sizing: border-box;\n}\n\n.mumak-guidance .mg-header {\n  border-left: 4px solid var(--gold);\n  padding-left: 16px;\n  margin-bottom: 20px;\n}\n\n.mumak-guidance .mg-eyebrow {\n  color: var(--gold);\n  font-size: 11px;\n  font-weight: 700;\n  letter-spacing: 1.3px;\n  text-transform: uppercase;\n}\n\n.mumak-guidance .mg-title {\n  color: var(--navy);\n  font-size: clamp(21px, 3vw, 27px);\n  font-weight: 700;\n  margin: 6px 0;\n  line-height: 1.3;\n}\n\n.mumak-guidance .mg-subtitle {\n  color: #6B7280;\n  font-size: 13px;\n  margin: 0;\n}\n\n.mumak-guidance .mg-table-wrap {\n  width: 100%;\n  overflow-x: auto;\n  border: 1px solid #E5E7E8;\n  border-radius: 12px;\n}\n\n.mumak-guidance table {\n  width: 100%;\n  border-collapse: collapse;\n  font-size: 13px;\n  min-width: 540px;\n}\n\n.mumak-guidance th {\n  background: var(--navy);\n  color: #FFFFFF;\n  padding: 14px 12px;\n  font-size: 11px;\n  font-weight: 700;\n  text-align: left;\n  letter-spacing: 0.4px;\n}\n\n.mumak-guidance td {\n  padding: 15px 12px;\n  border-bottom: 1px solid #E5E7E8;\n  vertical-align: middle;\n  line-height: 1.5;\n}\n\n.mumak-guidance tbody tr:nth-child(odd) {\n  background: var(--cream);\n}\n\n.mumak-guidance tbody tr:nth-child(even) {\n  background: #FFFFFF;\n}\n\n.mumak-guidance tbody tr:last-child td {\n  border-bottom: none;\n}\n\n.mumak-guidance .mg-old {\n  color: #737D86;\n  font-weight: 500;\n  white-space: nowrap;\n}\n\n.mumak-guidance .mg-new {\n  color: var(--green);\n  font-weight: 700;\n  white-space: nowrap;\n}\n\n.mumak-guidance .mg-note {\n  font-size: 11px;\n  color: #6B7280;\n  line-height: 1.6;\n  margin-top: 12px;\n}\n\n@media (max-width: 767px) {\n  .mumak-guidance table {\n    font-size: 12px;\n  }\n\n  .mumak-guidance th,\n  .mumak-guidance td {\n    padding: 11px 10px;\n  }\n}\n<\/style><section class=\"mumak-guidance\"><!-- \u00dcBERSCHRIFT --><div class=\"mg-header\"><div class=\"mg-eyebrow\">MUMAK \u00b7 UNTERNEHMENSUPDATE\n    <\/div><h2 class=\"mg-title\">Bayer | Prognose 2026\n    <\/h2><p class=\"mg-subtitle\">Bisherige und aktualisierte Jahresprognose\n    <\/p><\/div><!-- PROGNOSETABELLE --><div class=\"mg-table-wrap\"><table><thead><tr><th>Kennzahl<\/th><th>Bisherige Prognose<\/th><th>Neue Prognose<\/th><\/tr><\/thead><tbody><tr><td><strong>Konzern-EBITDA vor Sondereinfl\u00fcssen\n            <\/strong><\/td><td class=\"mg-old\">9,6 \u2013 10,1 Mrd. \u20ac\n          <\/td><td class=\"mg-new\">9,8 \u2013 10,3 Mrd. \u20ac\n          <\/td><\/tr><tr><td>EBITDA-Marge Pharmaceuticals\n            vor Sondereinfl\u00fcssen\n          <\/td><td class=\"mg-old\">23 \u2013 25 %\n          <\/td><td class=\"mg-new\">25 \u2013 27 %\n          <\/td><\/tr><tr><td>Free Cashflow\n          <\/td><td class=\"mg-old\">\u22122,5 bis \u2212 1,5 Mrd. \u20ac\n          <\/td><td class=\"mg-new\">\u22121,5 bis \u2212 0,5 Mrd. \u20ac\n          <\/td><\/tr><tr><td>Nettofinanzverschuldung\n            zum Jahresende\n          <\/td><td class=\"mg-old\">29 \u2013 30 Mrd. \u20ac\n          <\/td><td class=\"mg-new\">28 \u2013 29 Mrd. \u20ac\n          <\/td><\/tr><\/tbody><\/table><\/div><!-- QUELLE --><p class=\"mg-note\">Quelle: Bayer Quartalsmitteilung Q3 2026.\n  <\/p><\/section>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-944761a elementor-widget elementor-widget-text-editor\" data-id=\"944761a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 3 []\">The raised guidance reflects the improved profitability in the pharmaceutical business as well as the expectation of stronger cash flow development toward the end of the year.<\/p><p>However, expected free cash flow remains negative, while debt continues to be at a high level.<\/p><h2>Litigation and Financial Risks<\/h2><p>Ongoing legal proceedings related to Monsanto and Roundup remain a major uncertainty factor for Bayer.<\/p><p>Although individual US court decisions have recently favored the company, significant legal and financial risks remain.<\/p><p>Additional challenges arise from restructuring measures, the financing of existing liabilities, and ongoing investments in research and development.<\/p><p>The decisive factor will be whether the operational improvements lead to a sustainable increase in earnings and cash flow in the long term.<\/p><h2>Outlook: Can the Pharmaceutical Business Continue the Recovery?<\/h2><p>The third-quarter results show an improvement in operational development, particularly in the pharmaceutical business.<\/p><p>The growth of Nubeqa and Kerendia, along with further progress in drug development, could strengthen future earning power.<\/p><p>At the same time, a sustainable recovery depends on several factors: a stabilization of profitability in the agricultural business, an improvement in free cash flow, debt reduction, and a decrease in legal uncertainties.<\/p><p>The coming quarters will show whether the positive development of the Pharmaceuticals division can be transferred to the entire Group.<\/p><h2>Key Insights<\/h2><ul data-spread=\"false\"><li><p><strong>Pharmaceutical Business as Growth Driver:<\/strong> Nubeqa and Kerendia support revenue growth and rising operating profitability.<\/p><\/li><li><p><strong>Full-Year Guidance Raised:<\/strong> Bayer expects higher adjusted EBITDA and improved cash flow development for 2026.<\/p><\/li><li><p><strong>Challenges Remain:<\/strong> Negative free cash flow, weaknesses in the agricultural business, and existing legal risks continue to weigh on the financial outlook.<\/p><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4e31745 e-con-full e-flex e-con e-child\" data-id=\"4e31745\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8d6e245 elementor-widget elementor-widget-text-editor\" data-id=\"8d6e245\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p data-pm-slice=\"1 1 []\"><span style=\"color: #003366;\"><span style=\"color: #b58a2a;\"><strong>Key Takeaway: <\/strong><\/span><\/span>Bayer&#8217;s Q3 results show operational progress, particularly in the pharmaceutical business. The raised full-year guidance improves the earnings outlook. However, a sustainable financial recovery has yet to be confirmed.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Bayer Q3 2026: Rising revenue, strong pharmaceutical business, and raised guidance. An overview of the key results and risks.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[151],"tags":[431,380,329],"aktie":[],"class_list":["post-12447","post","type-post","status-publish","format-standard","hentry","category-company-update","tag-bayer","tag-healthcare-sector","tag-pharmaceutical-industry"],"acf":[],"_links":{"self":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/12447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/comments?post=12447"}],"version-history":[{"count":2,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/12447\/revisions"}],"predecessor-version":[{"id":12459,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/12447\/revisions\/12459"}],"wp:attachment":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/media?parent=12447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/categories?post=12447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/tags?post=12447"},{"taxonomy":"aktie","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/aktie?post=12447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}